Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-15 · accession 0000899243-23-005552 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-17 | 2023-02-15 | LGND | Korenberg Matthew E | Pres, COO | F - Tax | $72.98 | -2,890 | 89.7K | -3% | -$210.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-15 | F | D | 2,890 | $72.98 | 89,679 | D | — | — | (F1) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |